| Entry |
|
|---|
| Name |
Dasantafil (USAN/INN) |
|---|
| Formula |
C22H28BrN5O5
|
|---|
| Exact mass |
521.1274
|
|---|
| Mol weight |
522.3922
|
|---|
| Structure |
|
|---|
| Class |
Cardiovascular agent
DG01509 Phosphodiesterase V inhibitor
|
|---|
| Efficacy |
Impotence therapy, Phosphodiesterase V inhibitor |
|---|
| Comment |
Treatment of erectile dysfunction
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Cardiovascular agent
DG01509 Phosphodiesterase V inhibitor
D03657 Dasantafil
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE5
D03657 Dasantafil (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 33
1 N4y N 24.1134 -15.4334
2 C8y C 24.1134 -16.8357
3 N4y N 25.3278 -17.5368
4 C8y C 26.5423 -16.8357
5 C8y C 26.5423 -15.4334
6 C8y C 25.3278 -14.7323
7 N5x N 27.8759 -17.2690
8 C8y C 28.7002 -16.1346
9 N4y N 27.8759 -15.0001
10 O5x O 25.3278 -13.3302
11 C1b C 22.8990 -14.7323
12 C1a C 21.7016 -15.4238
13 O5x O 22.8990 -17.5368
14 C1b C 25.3278 -18.9389
15 C1b C 26.5253 -19.6304
16 O1a O 27.7145 -18.9439
17 N1b N 30.0731 -16.1346
18 C1b C 27.8759 -13.6001
19 C8y C 29.0849 -12.9020
20 C8x C 30.2617 -13.5813
21 C8x C 31.4741 -12.8812
22 C8y C 31.4739 -11.4812
23 C8y C 30.2971 -10.8019
24 C8x C 29.0848 -11.5020
25 X Br 30.2968 -9.3801
26 O2a O 32.7062 -10.7694
27 C1a C 33.9111 -11.4648
28 C1y C 30.7650 -17.3320
29 C1y C 32.1650 -17.3315
30 O1a O 32.8646 -16.1188
31 C1x C 30.3328 -18.6636
32 C1x C 31.4657 -19.4861
33 C1x C 32.5981 -18.6628
BOND 36
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 5 9 1
11 6 10 2
12 1 11 1
13 11 12 1
14 2 13 2
15 3 14 1
16 14 15 1
17 15 16 1
18 8 17 1
19 9 18 1
20 18 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 22 23 1
25 23 24 2
26 19 24 1
27 23 25 1
28 22 26 1
29 26 27 1
30 28 17 1 #Up
31 28 29 1
32 29 30 1 #Down
33 28 31 1
34 31 32 1
35 32 33 1
36 29 33 1
|
|---|
